Matches in SemOpenAlex for { <https://semopenalex.org/work/W2902790828> ?p ?o ?g. }
- W2902790828 endingPage "93" @default.
- W2902790828 startingPage "93" @default.
- W2902790828 abstract "Abstract Background: Outcomes to salvage therapy for patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) are suboptimal. Checkpoint blockade therapy (CBT) has been explored in the relapsed/refractory (R/R) NHL population, but response rates to single agent CBT therapy are modest. To date, there is no literature on whether treatment with CBT may sensitize NHL patients to subsequent therapy. We investigated the outcome of subsequent treatment in patients with R/R NHL who had received CBT in a large multicenter international retrospective analysis. Methods: Seventeen centers across the US and Canada are participating in this study to date. Medical records of each institution were queried to identify lymphoma patients who received CBT and were subsequently treated with an additional line of therapy. The primary aim of the current analysis was to determine the best response to post-CBT treatment in patients who discontinued CBT due to progression of disease (PD) or toxicity. Patients who discontinued CBT due to a complete response (CR), or patients whose best response to post-CBT therapy could not be determined due to death from another cause, were excluded from analysis. Responses were assessed using Lugano criteria. Survival status to date was analyzed for the entire study population and stratified by post-CBT treatment regimen categories and disease subgroups using the Kaplan-Meier method. Progression free survival (PFS) and overall survival (OS) were calculated for patients with at least stable disease (SD) to post-CBT treatment. Log rank tests were performed to test for statistical significance. Two-sided P<0.05 was considered to be statistically significant. Results: To date, out of 121 total lymphoma patients, we identified 42 NHL patients whom received therapy subsequent to CBT. The median age was 62 (range 27-85); 26 patients were men and 16 women. Twelve patients were stage 1-2, and 30 were stage 3-4. Forty patients, with 10 histologic subtypes (Table 1) were included in analysis. At least 24 patients (60%) had aggressive NHL; 12 (30%) had indolent histologies, and 4 (10%) were not otherwise specified (NOS). Seven patients had stem cell transplant (SCT) prior to CBT: 6 autologous (auto) and 1 allogeneic (allo). SCT occurred between 142 days and 8.3 years prior to treatment with CBT. The median number of treatments prior to CBT was 3 (range 1-9), and the median duration of response (DOR) to the treatment immediately prior to CBT was 2 months. The best response to CBT for these patients included: 4 partial response (PR), 11 SD, and 25 PD. Patients discontinued CBT due to PD (90%) and toxicity (10%). Post-CBT treatment regimens included standard chemotherapy (55%), targeted therapy (22.5%), and clinical trial drugs (22.5%). The overall response rate (ORR) to post-CBT treatment was 52.50% with 12 (30%) CR and 9 (22.5%) PR. Five patients (12.5%) had SD as their best response, and 14 (35.0%) PD. Of the patients with CR to post-CBT treatment, their best responses to CBT were PD for 6, SD for 4, and PR for 2. Currently, 13 patients have died: 12 from disease progression and 1 from AML, thus median overall survival (OS) has not been reached (Figure 1). Nine patients have not progressed on their subsequent therapy. For patients with CR, PR, or SD to post-CBT therapy, the median PFS is 12.5 months (Figure 2). The post-CBT treatment regimen used did not impact the survival outcome, and there is no significant evidence that post CBT treatment response and post CBT regimens are associated (Figure 3, Table 2). Fourteen patients had consolidative SCT after their post-CBT treatment: 11 allo and 3 auto. All of these patients remain alive and half have progressed. Conclusions: These data suggest that in a R/R NHL population, treatment with CBT may sensitize some patients to subsequent therapy even if they progress or do not respond to CBT. Patient survival and best response to post-CBT treatment were independent of the treatment regimen, but many of these treatments bridged patients to SCT. In many patients the post-CBT treatment responses with or without SCT were of a significantly greater duration than their pre-CBT DOR (2 months vs 1 year). For this population, especially if they are ineligible for SCT or CAR-T cell therapy, this may be a novel treatment approach. We plan to expand this analysis with additional patients prior to the December meeting. Disclosures Advani: Kura: Research Funding; Infinity: Research Funding; Kyowa: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board; Agensys: Research Funding; Janssen: Research Funding; Celgene: Research Funding; Bayer: Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board; Forty Seven Inc.: Research Funding; Roche/Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board, Research Funding; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Merck: Research Funding; Regeneron: Research Funding; Gilead/Kite: Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board; Cell Medica: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board; Autolus: Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board, Research Funding; Astra Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Participated in an advisory board, Research Funding; Millenium: Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Herrera:Immune Design: Research Funding; AstraZeneca: Research Funding; Merck, Inc.: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Seattle Genetics: Research Funding; Gilead Sciences: Research Funding; KiTE Pharma: Consultancy, Research Funding; Genentech: Consultancy, Research Funding. Chen:Affimed: Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding, Speakers Bureau; Millennium Pharmaceuticals: Consultancy, Research Funding; Genentech Inc.: Consultancy; Merck & Co., Inc.: Consultancy, Research Funding, Speakers Bureau. Ramchandren:Bristol-Myers Squibb: Consultancy; Seattle Genetics: Consultancy, Research Funding; Pharmacyclics LLC an AbbVie Company: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Merck: Research Funding. Assouline:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Honoraria, Research Funding, Speakers Bureau; Pfizer: Honoraria, Research Funding, Speakers Bureau; Roche: Honoraria, Research Funding, Speakers Bureau; Novartis: Research Funding. Wagner-Johnston:Celgene: Research Funding; Merck: Research Funding; Novartis: Research Funding; JUNO: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; ASTEX: Research Funding. Svoboda:Bristol-Myers Squibb: Consultancy, Research Funding; Regeneron: Research Funding; Merck: Research Funding; KITE: Consultancy; TG Therapeutics: Research Funding; Pharmacyclics: Consultancy, Research Funding; Kyowa: Consultancy; Seattle Genetics: Consultancy, Research Funding. Barta:Janssen: Membership on an entity's Board of Directors or advisory committees; Merck, Takeda, Celgene, Seattle Genetics, Bayer: Research Funding. Karmali:Gilead: Speakers Bureau; AstraZeneca: Speakers Bureau. Persky:Genentech: Honoraria; Morphosys (IDMC): Consultancy; Spectrum: Research Funding; Merck: Research Funding. Smith:BMS: Consultancy; Portola: Honoraria. Chavez:Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Speakers Bureau; Merck: Research Funding; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Humanigen: Consultancy. Diefenbach:Merck: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Incyte: Research Funding; Acerta: Research Funding; Millenium/Takeda: Research Funding; Denovo: Research Funding; Trillium: Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy." @default.
- W2902790828 created "2018-12-11" @default.
- W2902790828 creator A5000227859 @default.
- W2902790828 creator A5001204133 @default.
- W2902790828 creator A5003671711 @default.
- W2902790828 creator A5004343197 @default.
- W2902790828 creator A5005058090 @default.
- W2902790828 creator A5005159945 @default.
- W2902790828 creator A5007601060 @default.
- W2902790828 creator A5009486064 @default.
- W2902790828 creator A5013911840 @default.
- W2902790828 creator A5015361329 @default.
- W2902790828 creator A5019666650 @default.
- W2902790828 creator A5023363049 @default.
- W2902790828 creator A5030788778 @default.
- W2902790828 creator A5035030443 @default.
- W2902790828 creator A5036719866 @default.
- W2902790828 creator A5043430345 @default.
- W2902790828 creator A5047477600 @default.
- W2902790828 creator A5048753753 @default.
- W2902790828 creator A5050643493 @default.
- W2902790828 creator A5050727908 @default.
- W2902790828 creator A5052962596 @default.
- W2902790828 creator A5053410437 @default.
- W2902790828 creator A5056912326 @default.
- W2902790828 creator A5059757869 @default.
- W2902790828 creator A5060314041 @default.
- W2902790828 creator A5065588144 @default.
- W2902790828 creator A5067043341 @default.
- W2902790828 creator A5073861459 @default.
- W2902790828 creator A5074696156 @default.
- W2902790828 creator A5074729432 @default.
- W2902790828 creator A5081175603 @default.
- W2902790828 creator A5084789778 @default.
- W2902790828 creator A5090212603 @default.
- W2902790828 date "2018-11-29" @default.
- W2902790828 modified "2023-09-27" @default.
- W2902790828 title "Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy" @default.
- W2902790828 doi "https://doi.org/10.1182/blood-2018-99-117448" @default.
- W2902790828 hasPublicationYear "2018" @default.
- W2902790828 type Work @default.
- W2902790828 sameAs 2902790828 @default.
- W2902790828 citedByCount "0" @default.
- W2902790828 crossrefType "journal-article" @default.
- W2902790828 hasAuthorship W2902790828A5000227859 @default.
- W2902790828 hasAuthorship W2902790828A5001204133 @default.
- W2902790828 hasAuthorship W2902790828A5003671711 @default.
- W2902790828 hasAuthorship W2902790828A5004343197 @default.
- W2902790828 hasAuthorship W2902790828A5005058090 @default.
- W2902790828 hasAuthorship W2902790828A5005159945 @default.
- W2902790828 hasAuthorship W2902790828A5007601060 @default.
- W2902790828 hasAuthorship W2902790828A5009486064 @default.
- W2902790828 hasAuthorship W2902790828A5013911840 @default.
- W2902790828 hasAuthorship W2902790828A5015361329 @default.
- W2902790828 hasAuthorship W2902790828A5019666650 @default.
- W2902790828 hasAuthorship W2902790828A5023363049 @default.
- W2902790828 hasAuthorship W2902790828A5030788778 @default.
- W2902790828 hasAuthorship W2902790828A5035030443 @default.
- W2902790828 hasAuthorship W2902790828A5036719866 @default.
- W2902790828 hasAuthorship W2902790828A5043430345 @default.
- W2902790828 hasAuthorship W2902790828A5047477600 @default.
- W2902790828 hasAuthorship W2902790828A5048753753 @default.
- W2902790828 hasAuthorship W2902790828A5050643493 @default.
- W2902790828 hasAuthorship W2902790828A5050727908 @default.
- W2902790828 hasAuthorship W2902790828A5052962596 @default.
- W2902790828 hasAuthorship W2902790828A5053410437 @default.
- W2902790828 hasAuthorship W2902790828A5056912326 @default.
- W2902790828 hasAuthorship W2902790828A5059757869 @default.
- W2902790828 hasAuthorship W2902790828A5060314041 @default.
- W2902790828 hasAuthorship W2902790828A5065588144 @default.
- W2902790828 hasAuthorship W2902790828A5067043341 @default.
- W2902790828 hasAuthorship W2902790828A5073861459 @default.
- W2902790828 hasAuthorship W2902790828A5074696156 @default.
- W2902790828 hasAuthorship W2902790828A5074729432 @default.
- W2902790828 hasAuthorship W2902790828A5081175603 @default.
- W2902790828 hasAuthorship W2902790828A5084789778 @default.
- W2902790828 hasAuthorship W2902790828A5090212603 @default.
- W2902790828 hasConcept C126322002 @default.
- W2902790828 hasConcept C143998085 @default.
- W2902790828 hasConcept C170493617 @default.
- W2902790828 hasConcept C203014093 @default.
- W2902790828 hasConcept C2778468042 @default.
- W2902790828 hasConcept C2779338263 @default.
- W2902790828 hasConcept C71924100 @default.
- W2902790828 hasConceptScore W2902790828C126322002 @default.
- W2902790828 hasConceptScore W2902790828C143998085 @default.
- W2902790828 hasConceptScore W2902790828C170493617 @default.
- W2902790828 hasConceptScore W2902790828C203014093 @default.
- W2902790828 hasConceptScore W2902790828C2778468042 @default.
- W2902790828 hasConceptScore W2902790828C2779338263 @default.
- W2902790828 hasConceptScore W2902790828C71924100 @default.
- W2902790828 hasIssue "Supplement 1" @default.
- W2902790828 hasLocation W29027908281 @default.
- W2902790828 hasOpenAccess W2902790828 @default.
- W2902790828 hasPrimaryLocation W29027908281 @default.
- W2902790828 hasRelatedWork W1979600966 @default.
- W2902790828 hasRelatedWork W2035896770 @default.
- W2902790828 hasRelatedWork W2051519978 @default.